Abstract
In this work, we tested the pharmacotoxicological profile of three new nitro-anti-inflammatory agents, nitrofenac, nitronaproxen and mtroflurbiprofen with the following results:
-
1
In models of acute (carrageenan oedema) and chronic (adjuvant arthritis) inflammation in the rat, the nitroderivatives, compared with the parent drugs, showed similar anti-inflammatory properties by significantly inhibiting both oedema volume and arthritis development.
-
2
The nitroso compounds showed markedly less ulcerogenic activity compared with the parent drugs both in acute conditions and at t he end of the chronic inflammation test.
-
3
The lack of gastrointestinal damage observed with these new anti-inflammatory drugs is the consequence of their ability to release NO. This hypothesis is supported by pharmacokinetic studies and a significant increase in nitrite/nitrate plasma levels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Garner A. Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol. 1992;27:83–9.
Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-flammatory drugs and peptic ulcer disease. Ann Intern Med. 1991;114:307–19.
Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology. 1981;80:94–8.
Radomski MW, Palmer RMJ, Read NG, Moncada S. Isolation and washing of human platelets with nitric oxide. Thromb Res. 1988;50:537–46.
Pique JM, Whittle BJR, Esplugues N. The vasodilator role of endogenous nitric oxide in the rat gastric microcirculation. Eur J Pharmacol. 1989;174:293–6.
Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651–5.
Conforti A, Donini M, Brocco G, Del Soldato P, Benoni G, Cuzzolin L. Acute antiinflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac. Agents Actions. 1993;40:176–80.
Cuzzolin L, Conforti A, Adami A et al. Antiinflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. Pharm Res. 1995;31:61–5.
Cuzzolin L, Conforti A, Donini M, Adami A, Del Soldato P, Benoni G. Effects on intestinal microflora, gastrointestinal tolerability and antiinflammatory efficacy of diclofenac and nitrofenac in adjuvant arthritic rats. Pharm Res. 1994;29:89–97.
Mitchell JA, Cirino G, Akarasereenont P, Wallace JL, Flower RJ, Vane JR. Flurbinitroxybutylester: a novel antiinflammatory drug devoid of ulcerogenic activity, inhibits cyclooxygenase-1 and cyclooxygenase-2. Can J Physiol Pharmacol. 1994;72:270.
Mariotto S, Menegazzi M, Carcereri de Prati A et al. Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivative, nitroflurbiprofen. Br J Pharmacol. 1995;115:ii.
Wallace JL, Reuter B, Cicala C, McKnight GW, Grisham MB, Cirino G. Novel NSAID derivatives with markedly reduced ulcerogenic properties. Gastroenterology. 1994;107:173–9.
Wallace JL, Cirino G, McKnight GW, Elliott S. Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester. Eur J Pharmacol. 1995;280:63–8.
Benoni G, Terzi M, Adami A, Grigolini L, Del Soldato P, Cuzzolin L. Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. J Pharm Sci. 1995;84:93–5.
Bartholomew B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of E. coll. Food Chem Toxicol. 1984;22:541–3.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and 15[N]nitrate in biological fluids. Anal Biochem. 1982;126:131–8.
Mariotto S, Cuzzolin L, Adami A, Del Soldato P, Suzuki H, Benoni G. Effect of a new nonsteroidal antiinflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. Br J Pharmacol. 1995;115:225–6.
Baydoun AR, Cirino G, Wallace JL. Elevation of cGMP in human endothelial cells by flurbiprofennitroxybutylester, a novel nonsteroidal antiinflammatory drug with reduced ulcerogenic actions in vivo. Br J Pharmacol. 1995;114:71.
Wallace JL, Del Soldato P, Cirino G. Development of NSAIDs with reduced gastrointestinal and renal toxicity. Exp Opin Invest Drugs. 1995;4:613–19.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Del Soldato, P., Cuzzolin, L., Adami, A., Conforti, A., Crivellente, F., Benoni, G. (1997). Nitric Oxide-Releasing NSAIDs, a Novel Class of Safe and Effective Anti-Inflammatory Agents. In: Rainsford, K.D. (eds) Side Effects of Anti-Inflammatory Drugs IV. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5394-2_25
Download citation
DOI: https://doi.org/10.1007/978-94-011-5394-2_25
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6269-5
Online ISBN: 978-94-011-5394-2
eBook Packages: Springer Book Archive